To test the hypothesis, recombinant human IL‐38 was then adopted to stimulate PBMCs of patients with SLE, showing that IL‐38 can effectively down‐regulate the synthesis of these inflammatory components. The gene discussed is IL1F10; the disease is systemic lupus erythematosus.